Screener
Recursion Pharmaceuticals, Inc. RXRX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Unearned revenue | 27,586 | 37,605 |
| Operating lease liabilities | 13,249 | 12,663 |
| Notes payable and financing lease liabilities | 9,443 | 9,091 |
| Total current liabilities | 119,886 | 147,707 |
| Unearned revenue, non-current | 112,818 | 114,012 |
| Operating lease liabilities, non-current | 39,193 | 46,647 |
| Notes payable and financing lease liabilities, non-current | 4,753 | 9,564 |
| Deferred tax liabilities | 18,313 | 23,255 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s total current liabilities?
- Recursion Pharmaceuticals, Inc. (RXRX) reported total current liabilities of $119.89M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s total current liabilities changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s total current liabilities decreased by 26.9% year-over-year, from $164.03M to $119.89M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s total current liabilities has grown at a 44.9% compound annual growth rate (CAGR), from $23.1M to $147.71M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Recursion Pharmaceuticals, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude